What is FlowMetric?
FlowMetric operates as a premier contract research organization (CRO) specializing in flow cytometry and cell sorting solutions. Headquartered in Doylestown, Pennsylvania, the firm provides essential analytical services that span the entire drug development lifecycle, from preclinical research and non-GLP/GLP toxicology studies to comprehensive support for Clinical Phase 0-IV trials. By integrating advanced cytometry technology into precision medicine, FlowMetric enables global pharmaceutical partners to accelerate therapeutic discovery and validate clinical outcomes with high-fidelity data. Their dual-presence through FlowMetric and FlowMetric Europe allows for seamless international collaboration, positioning the company as a linchpin in the modern biotech infrastructure.
How much funding has FlowMetric raised?
FlowMetric has raised a total of $2.1M across 3 funding rounds:
Private Equity
$926K
Private Equity
$820K
Debt
$350K
Private Equity (2015): $926K, investors not publicly disclosed
Private Equity (2017): $820K, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Key Investors in FlowMetric
PPP
Public-Private Partnership
Undisclosed Investor
A private equity partner focused on long-term value creation within the life sciences and contract research sectors.
Undisclosed Investor
A strategic capital provider specializing in high-growth healthcare services and clinical research infrastructure.
What's next for FlowMetric?
With the recent influx of capital, FlowMetric is well-positioned to expand its technical capabilities and geographic footprint. The strategic focus will likely center on enhancing high-throughput screening capacities and deepening its expertise in emerging therapeutic areas. As the demand for precision medicine continues to rise, the company is expected to leverage its current financial standing to invest in next-generation instrumentation and talent acquisition. This growth phase will be critical in maintaining its competitive edge as a full-service CRO, particularly as it navigates the increasingly complex regulatory landscape of global clinical trials. Future initiatives will likely prioritize the integration of automated data analysis workflows to further streamline the drug development pipeline for its diverse client base.
See full FlowMetric company page
